AI and Gene Therapy Alliance Expands to Parkinson's and Eye Diseases: U.S. Biotech Accumulates Cash Reserves

MeiraGTx Holdings plc (Nasdaq: MGTX), a U.S.–U.K.–based gene therapy company, announced on March 26 its fourth-quarter and full-year 2025 results, highlighting that its lead candidate for radiation-induced grade 2 and 3 xerostomia, AAV2-hAQP1, has received Breakthrough Therapy Designation from the U.S. FDA. The company also secured RMAT (Regenerative Medicine Advanced Therapy) designation for its AAV-GAD program in Parkinson’s disease and is preparing to enter Phase 3. MeiraGTx forged a joint venture with AI specialist Hologen, featuring approximately $200 million in upfront payments and up to $230 million in additional funding, and signed a $75 million global ophthalmology and “RevoSwitch” asset partnership with Eli Lilly. For 2025, net loss narrowed to $114.2 million, and MeiraGTx reported that its existing cash and partner funding will support operations through mid-2027 and enable repayment of its Perceptive Credit facility due in 2026.

On April 15, MeiraGTx subsidiaries and Janssen mutually terminated their 2023 asset-transfer, conversion, supply and quality agreements for the RPGR gene therapy program. In their place, MeiraGTx Ocular entered a new asset-purchase agreement to reacquire all RPGR-related assets and rights, with both parties waiving future milestone and supply-payment claims. Then on April 20, MeiraGTx and Hologen amended their 2025 manufacturing-company equity framework to establish a two-step share-acquisition structure—initial stake purchase followed by additional closings after foreign-investment review—to reach a target ownership. The amendment also grants Hologen a call option to increase its stake to 40% and MeiraGTx a put option, formalizing key changes to the capital and governance structure.

Recently, MeiraGTx announced it has reacquired Botaretigene Sparoparvovec (“Bota-Vec”), its X-linked retinitis pigmentosa gene therapy, from a Johnson & Johnson affiliate for $25 million and is preparing simultaneous U.S. and EU regulatory filings targeting a 2027 launch. On April 16, in an investor call, the company released three-year follow-up data from its Phase 1 AQUAx study in radiation-induced xerostomia and outlined plans for a pivotal Phase 2 trial aiming for a BLA submission in 2027 and product launch in 2028.

MeiraGTx is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic, salivary-gland and central nervous system disorders. Its late-stage pipeline includes candidates for Parkinson’s disease, radiation-induced xerostomia, AIPL1-related congenital blindness and X-linked retinitis pigmentosa. As the high-value gene-therapy market expands, MeiraGTx is combining co-development and licensing partnerships with major pharma alongside in-house manufacturing to pursue commercialization—an example of how technology and assets flow between big pharma and smaller biotechs in the U.S. gene-therapy sector.